当前位置: 首页 > 期刊 > 《世界中医药》 > 20184
编号:13599573
百令胶囊联合吸入舒利迭治疗慢性阻塞性肺疾病稳定期患者的疗效及对肺功能和营养指标的影响(1)
http://www.100md.com 2018年2月15日 《世界中医药》 20184
     摘要 目的:探讨百令胶囊联合吸入舒利迭治疗慢性阻塞性肺疾病(COPD)稳定期患者的疗效及对肺功能和营养指标的影响。方法:选取2016年6月至2017年6月遂宁市中心医院收治的COPD稳定期患者60例,按照随机数字表法分为观察组与对照组,每组30例。观察组采用百令胶囊联合舒利迭治疗,对照组仅采用舒利迭治疗。2组疗程均为3个月。比较2组临床疗效,治疗前后肺功能、营养指标及主要症状积分变化。结果:观察组治疗总有效率(96.67%)高于对照组(70.00%)(P<0.05)。2组治疗后FEV1、FEV1/FVC、FEV1预计值增加(观察组:t=6.731 0、14.470 4、10.850 9,對照组:t=3.170 7、7.752 6、5.920 5,P<0.05);观察组治疗后FEV1、FEV1/FVC、FEV1预计值高于对照组(t=3.474 3、6.708 4、4.585 3,P<0.05)。2组治疗后BMI、ALB、Palb和TSF增加(观察组:t=6.013 1、11.223 5、12.314 1、10.822 9,对照组:t=2.713 4、4.495 9、4.899 6、3.887 3,P<0.05);观察组治疗后BMI、ALB、Palb和TSF高于对照组(t=3.504 0、5.665 1、7.043 2、6.905 6,P<0.05)。2组治疗后咳嗽、咳痰、喘息积分降低(观察组:t=13.265 0、14.531 3、14.938 7,对照组:t=9.446 9、9.524 6、9.555 5,P<0.05);观察组治疗后咳嗽、咳痰、喘息积分低于对照组(t=13.701 6、8.224 7、11.627 6,P<0.05)。结论:百令胶囊联合吸入舒利迭治疗COPD稳定期患者疗效明显,且可改善患者肺功能和营养状态。

    关键词 百令胶囊;舒利迭;慢性阻塞性肺疾病;稳定期;疗效;肺功能;营养指标;临床意义

    Abstract Objective:To investigate the clinical effect of Bailing Capsule combined with inhalation of seretide in the treatment of chronic obstructive pulmonary disease (COPD) patients in the stable period and the effect on pulmonary function and nutritional index.Methods:A total of 60 cases of COPD stable patients admitted in our hospital from June 2016 to June 2017 were randomly divided into observation group (30 cases) and control group (30 cases).The observation group was treated with Bailing Capsule combined with Seretide treatment,and control group was only received Seretide treatment.The two groups were treated for 3 months.The therapeutic effects of the two groups were compared.The changes of lung function,nutritional index and main symptom scores before and after treatment were compared.Results:The total effective rate of the observation group (96.67%) was higher than that of the control group (70.00%) (P<0.05).The expected value of FEV1,FEV1/FVC,FEV1 of two groups after treatment was increased (the observation group:t=6.731 0,14.470 4,10.850 9,the control group:t=3.170 7,7.752 6,5.920 5,P<0.05); The expected value of FEV1,FEV1/FVC,FEV1 of the observation group after treatment was higher than that of the control group (t=3.474 3,6.708 4,4.585 3,P<0.05).The two groups after treatment BMI,ALB,Palb and TSF increased (observation group:t=6.013 1,11.223 5,12.314 1,10.822 9,the control group:t=2.713 4,4.495 9,4.899 6,3.887 3,P<0.05); BMI,ALB,Palb and TSF of the observation group after treatment was higher than the control group (t=3.504 0,5.665 1,7.043 2,6.905 6,P<0.05).Cough,sputum and wheezing scores decreased in two groups after treatment (observation group:t=13.265 0,14.531 3,14.938 7,the control group:t=9.446 9,9.524 6,9.555 5,P<0.05); cough,expectoration,gasp score of the observation group after treatment was lower than the control group (t=13.701 6,8.224 7,11.627 6,P<0.05).Conclusion:Bailing Capsule combined inhaled Seretide in the treatment of patients with stable COPD has obvious effect,and can improve the pulmonary function and nutritional status of patients,with important research significance., 百拇医药(李博 何正光 杨帆 杜发旺)
1 2 3 4下一页